Screening with prostate-specific antigen (PSA) combined with systematic prostate biopsies reduces prostate cancer (PCa) mortality [1], [2], [3], [4] but poses risks of overdiagnosis and overtreatment of clinically insignificant tumours [5], [6]. The gene discussed is KLK3; the disease is posterior cortical atrophy.